OBJECTIVE： To make a textual research on the normal name， synonym and Chinese translation name aiming at the phenomenon of more than one name of Tibetan medicine “Riguan”， and to determine the standard name suitable for standardization and popularization. METHODS： The representative classical Tibetan medicine books from the 7th to the 21st century were studied. The names of “Riguan” in various books and their occurrence frequency， naming basis and succession were sorted out， and the standard names of “Riguan” in Tibetan and Chinese were screened for easy understanding and popularization. RESULTS： According to the 17 representative Tibetan medicine classics books and 6 Chinese version Tibetan medicine books， “Riguan” had 19 Tibetan names. Among them， the most frequently recorded name was “Zimagangjiu”， which had been recorded in 11 books. Secondly， “Riguan” and “Puronggang” were recorded in 8 books respectively， and “Riguanzima” was recorded in 7 books. Naming basis could be summarized into four categories， i.e. simple naming （such as “Riguan”）， emphasizing morphological characteristics （such as “Zimagangjiu”）， emphasizing medicinal properties （such as “Daweitou”）， simple naming+emphasizing morphological characteristics （such as “Riguanzima”）. “Zimagangjiu” “Riguan” and “Riguanzima” were used as normal names in the 7th to 8th century， 8th to 19th century and 19th to 21st century respectively. Among them， “Riguanzima” was first recorded in the official book Tibetan Medicine Subvolume of Chinese Medical Encyclopedia as a formal name， which symbolized the milestone of the development of Tibetan medicine in the new era of our country. CONCLUSIONS： According to the naming basis and current application situation， it is suggested that “Riguanzima” can be used as the Tibetan and Chinese standard name of Tibetan medicine “Riguan” to promote and standardize its application.

Osteoarthritis （OA） and stroke are common clinical diseases that reduce patients' quality of life and place a burden on families and society. Ruyi Zhenbaowan， a classic prescription in Tibetan medicine， have the functions of clearing heat， awakening the brain and opening orifices， relaxing tendons and promoting meridian circulation， and eliminating yellow water. Clinically， they are used to treat osteoarthritis， post-stroke sequelae， neuropathic pain， and other related conditions. Modern pharmacological studies have demonstrated their anti-inflammatory， analgesic， and nerve-repairing effects. However， current research remains insufficient regarding the appropriate indications， timing， and efficacy of this medicine in treating relevant diseases. To enhance clinicians' understanding of this medicine and promote its standardized and rational clinical use， a panel of national experts， including clinical specialists， Tibetan medicine practitioners， pharmacologists， and methodologists， formulated this consensus based on clinical experience and evidence-based practice. The Cochrane systematic review framework， the Grading of Recommendations Assessment， Development and Evaluation （GRADE） system， and the nominal group method were employed to generate seven graded recommendations and 19 consensus-based suggestions. These recommendations clearly define the key points in the clinical application of Ruyi Zhenbaowan， including therapeutic indications， dosage and administration， treatment duration， and medication safety. The consensus specifically addresses the clinical efficacy， appropriate timing of administration， dosage strategies， treatment cycles， and combination medication strategies for treating osteoarthritis and stroke and provides an overview of safety considerations. The aim is to provide standardized guidance for hospitals and healthcare institutions nationwide to ensure the rational application of Ruyi Zhenbaowan in the treatment of osteoarthritis and stroke， reduce medication-related risks， and further leverage its clinical advantages. This consensus has been approved and issued by the China Association of Chinese Medicine， with the standard number GS/CACM 369-2024.